Viridian Therapeutics (VRDN) appears to be ending on a high note in 2024, because it just reported positive results from its phase 3 THRIVE-2 study using its anti-IGF-1R drug veligrotug [VRDN-001] to ...
Acelyrin, Inc. (SLRN) announced a strategic shift back in August 2024, stating that despite the positive data it achieved with its drug Izokibep in treating patients with hidradenitis suppurativa [HS] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results